The Pharmacodynamics Optimiza Resistant Staphylococcus aureus In E Setiawan1,2*,P Montakantikul1, B 1
Faculty of Pharmacy, Mahidol Univ 2
Faculty of Pharmacy, University of
Keywords: Vancomycin, Methicill Background
There are increasing number of artic
Staphylococcus aureus (MRSA) with cornerstone treatment of MRSA infe MRSA coverage antibiotics. Owing treatment for MIC 1.5mg/L and 2mg desired PK-PD indices in MRSA-inf
Methods
Monte Carlo simulation by using 10, regimens ranging from 1g every 6, 8 from population PK study conducted intermittent dosage regimen was calc
≥400 for MIC 1.5mg/L and 2.0mg/L
Results
Dosage regimen 1g every 12h couldn Considering the MRSA with MIC 1. >80%. However, if particular condit should be recommended as the most dosage regimens 4g/day, either given regimens could afford PTA >90% fo steady state condition.
Conclusions
Intermittent dosage regimen at least MRSA with MIC 1.5mg/L and 2.0m determining the best intermittent dos needed to determine the most approp the 1st 24h.
ization of Intermittent Vancomycin Dosage Regimens Infections with MIC of 1.5 and 2.0 mg/L in Thai Pop
, B Chindavijak1
niversity, Bangkok, Thailand. of Surabaya, East Java, Indonesia.
cillin-Resistant Staphylococcus aureus, Pharmacodyna
ticles questioning the efficacy of vancomycin to treat me ith MIC 1.5mg/L and 2.0mg/L. However, vancomycin i nfection particularly in most of developing countries with ng to the interest whether vancomycin still enable to be u
mg/L, present study was conducted to analyze the achiev infected Thai population.
10,000 replications was performed for several vancomyc , 8, 12h, 1.5g and 2 g every 12h. Vancomycin concentra ted in 212 Thai population. The probability of target atta alculated from the number of simulated patients who ach /L divided by total number of replication.
ldn’t afford desired PTA for MRSA with MIC 1.5mg/L 1.5mg/L, dosage regimen 1g every 8h and 1.5g every 12 ditions required PTA >90%, dosage regimen 1g every 6 ost appropriate dosage regimen. While, for MRSA with M
ven as 1g every 6h or 2g every 12h, could afford PTA >8 for MRSA with MIC 2.0mg/L. All PTA achievement re
st 3g/day and 4g/day were needed to afford desired PTA 0mg/L, respectively. Finding of present study could be u dosage regimen in documented vancomycin treatment. F ropriate intermittent dosage regimen that could achieve t
ens in Methicillin-opulation
ynamics
methicillin-resistant in is still used as the
ith limited alternative e used as the cornerstone ievement of vancomycin
ycin intermittent dosage trations were estimated
ttainment (PTA) of each achieved AUC24/MIC
/L and 2.0mg/L. 12h could afford PTA 6 hours or 2g every 12h h MIC 2.0mg/L, only >80%. No any dosage t represented the PTA at
TA achievement for e used as a guidance in
